Global Cancer Drugs Market: Key Developments
In June 2023, the Food & Drug Administration (FDA) granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
In May 2023, the Food & Drug Administration (FDA) approved Olaparib (Lynparza, AstraZeneca Pharmaceuticals) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC), as determined by an FDA-approved companion diagnostic test.
In May 2023, the Food and Drug Administration (FDA) granted accelerated approval to Epkinly (epcoritamab-bysp, Genmab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients